curdlan has been researched along with rifampin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dube, A; Fonteh, P; Hayeshi, R; Khumalo, V; Labuschagne, P; Lubuschagne, P; Madziva, MT; Meyer, D; Naicker, B; Ndamase, A; Swai, H; Tukulula, M | 1 |
| Doble, M; T S, SK; Yunus Basha, R | 1 |
| Arumugam, SK; Doble, M; Mitra, K; Ravindran, R | 1 |
3 other study(ies) available for curdlan and rifampin
| Article | Year |
|---|---|
Curdlan-Conjugated PLGA Nanoparticles Possess Macrophage Stimulant Activity and Drug Delivery Capabilities.
Topics: Antitubercular Agents; beta-Glucans; Biological Transport, Active; Caco-2 Cells; Carbohydrate Sequence; Cell Membrane Permeability; Cell Survival; Chemistry, Pharmaceutical; Drug Delivery Systems; Excipients; Humans; Intestinal Absorption; Lactic Acid; Macrophages; Molecular Sequence Data; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rifampin; Stimulation, Chemical | 2015 |
Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages.
Topics: Animals; Antitubercular Agents; beta-Cyclodextrins; beta-Glucans; Cell Line; Drug Carriers; Drug Liberation; Levofloxacin; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium smegmatis; Nanoparticles; Rifampin | 2019 |
Preparation of Curdlan sulphate - Chitosan nanoparticles as a drug carrier to target Mycobacterium smegmatis infected macrophages.
Topics: Animals; beta-Glucans; Cell Survival; Chitosan; Drug Carriers; Drug Delivery Systems; Drug Liberation; Endocytosis; Hydrogen-Ion Concentration; Inflammation; Kinetics; Macrophages; Mice; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Nanoparticles; Polyelectrolytes; Polymers; RAW 264.7 Cells; Rifampin | 2021 |